40 results about "Blood markers" patented technology

The invention discloses a machine learning-based intra-operative bleeding risk prediction method and device for spinal surgery. The machine learning-based intraoperative bleeding risk prediction method for spinal surgery comprises the following steps: acquiring information of a patient to be predicted; obtaining a trained hemorrhage risk prediction model; and inputting the information of the patient to be predicted into the trained massive hemorrhage risk prediction model so as to obtain a prediction result. According to the method, the high-precision prediction model is trained through large-scale patient data (including basic information, operation parameters, blood indexes and the like), so that the accuracy and the stability of intraoperative SBL risk prediction are improved. And a Cell Saver use suggestion based on a risk threshold is provided, and blood resource allocation is optimized. Clinical decision-making efficiency is improved through an automatic tool, blood transfusion related complications (such as infection and immune response) are reduced, and patient prognosis is improved.

The invention belongs to the field of biological medicine industry, and discloses a blood marker for assisting in diagnosing influenza. The inventor verifies that the LRG1 is a peripheral blood marker of influenza for the first time and can be used for auxiliary diagnosis of influenza and increase of the detection rate of influenza virus by being matched with multiple times of detection of influenza virus. A test result shows that the peripheral blood LRG1 content 5ng / ml is a CUTOFF value, 46 patients and 4 false negative patients are successfully detected for 50 influenza patients, and the sensitivity is 92%; the number of normal persons is 60, the number of the normal persons is 12, and the specificity is 80%. After influenza treatment, LRG1 and Plt are obviously reduced compared with those before influenza treatment; 0.001, which is equivalent to the level of normal people, Pgt; and 0.05%.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

To provide an estimation method of a recirculation rate enabling estimation of a recirculation rate without being limited by a preparation location of a blood marker or an arrangement location of detection means of the blood marker.SOLUTION: An estimation method of a recirculation rate includes the steps of: acquiring data representing an amount of change in blood concentration after recirculation when a blood marker is added to blood to be extracorporeally circulated, data representing a relation between an amount of change in blood concentration after recirculation and blood concentration, and data representing a relation between the amount of change in blood concentration after recirculation and a blood flow rate; creating a model by multivariate analysis or machine learning to obtain a regression equation or a conversion model, with the amount of change in blood concentration after recirculation, blood concentration and a blood flow rate used as an explanatory variables and the recirculation rate as an objective variable; acquiring data representing the amount of change in blood concentration, blood concentration and a blood flow rate of blood flowing through an arterial line or a venous line; and inputting treatment data to the regression equation or the conversion model to estimate the recirculation rate.SELECTED DRAWING: Figure 3A

The invention belongs to the field of biological medicine industry, and discloses a peripheral blood marker and system for identifying the severity of viral myocarditis or coronary artery stenosis. The inventor finds for the first time that the average value of LRG1 in blood is not obviously changed compared with that of a normal person when mild and moderate myocarditis and microcirculation angina pectoris with normal coronary artery or coronary artery stenosis smaller than 10% exist, and the blood LRG1 is obviously increased when the coronary artery stenosis of the coronary heart disease exceeds 70%; when severe myocarditis occurs, the blood LRG1 is also obviously increased, so that the increase of the blood LRG1 is a blood marker for patients with severe myocarditis or severe coronary artery lesion, and the blank that blood indexes are lacked in the prior art to prompt the patients to have severe coronary artery stenosis is filled. By detecting the LRG1 content of the peripheral blood and combining with other conventional examinations, the severity of myocarditis or coronary stenosis can be simply, accurately and quickly distinguished, and a corresponding basis is provided for subsequent accurate treatment.

The invention provides an auxiliary detection system for diagnosing Alzheimer's disease, which relates to the technical field of classification diagnosis of Alzheimer's disease, and comprises a data acquisition module, a data processing module, a feature extraction module, a diagnosis model module and a report generation module, according to the method, four types of core data including clinical information, scale scores, MRI images and blood biomarkers are integrated, the core dimension of Alzheimer's disease diagnosis is covered, so that the pathological evolution of AD from molecular abnormality to structural damage can be more comprehensively captured by utilizing collaborative analysis of multi-modal features, and the diagnosis accuracy of the Alzheimer's disease is improved. The problem of missed diagnosis or misdiagnosis caused by single modal data is avoided, and the diagnosis accuracy is improved. And secondly, aiming at the heterogeneity problem of image data and blood marker data, a standardized processing technology is adopted, so that the consistency of data of different sources and different batches is ensured, the influence of equipment difference and experimental error is eliminated, and a reliable guarantee is provided for model input.

The invention discloses an immunosensor for detecting Alzheimer's disease neurofilament light chain protein based on a two-dimensional metal organic framework and a preparation method of the immunosensor, and belongs to the technical field of biological detection sensors. An electrode modified with a RuMOFNSs-Ab2 conjugate and an Au-coated MoS2-Ab1 conjugate is used as a working electrode; the sandwich type electrochemical luminescence immunosensor is based on the two-dimensional RuMOFNSs / Au-coated MoS2, can be used for detecting the blood marker NfL of the Alzheimer's disease, provides a thought for the field of analysis and detection of the NfL, and also provides a reference for clinical medicine detection.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.

The invention belongs to the technical field of Alzheimer's disease marker detection, and particularly relates to an Alzheimer's disease blood marker joint detection kit and a manufacturing method thereof.The kit comprises a protein chip, the protein chip comprises a chip base and marker antibodies coating the chip base, the marker antibodies comprise anti-A beta (1-40) IgG, anti-A beta (1-42) IgG, anti-T-Tau IgG, anti-P-Tau181IgG, anti-P-Tau217 IgG and anti-S100 beta IgG, the chip base is coated with the marker antibodies, and the chip base is coated with the marker antibodies. The Alzheimer's disease blood marker joint detection kit is high in sensitivity, specificity and accuracy, stable in result, good in repeatability and convenient and fast to operate, saves manpower and material resources, is a reliable tool means for early diagnosis of Alzheimer's disease by medical workers, and improves the labor efficiency. The patient can be treated earlier, and the survival rate is increased.

According to an aspect of the present invention, there is provided computer-implemented method for forecasting near-term sudden cardiovascular events, comprising: pretraining a large language model transformer architecture using a processor with an associated computer memory device to recognize text associated with sudden cardiovascular events cases reporting sudden cardiovascular events following a medical exam appointment; obtaining relevant data regarding an asymptomatic individual comprising one or more of a coronary artery calcium (CAC) scan, a coronary CT angiography (CCTA), chest CT, blood markers, and electrocardiogram; providing the relevant data of the asymptomatic individual to the trained computer-implemented artificial neural network; receiving a forecast of the chance of near-term sudden cardiovascular events in the asymptomatic individual; and recommending the next diagnostic or therapeutic step for the asymptomatic individual.

The invention provides a method for predicting nasopharyngeal carcinoma stem cell depletion characteristics by using a blood marker, which comprises the following steps: acquiring cancer tissue samples of a plurality of nasopharyngeal carcinoma patients, and constructing a transcriptome-based nasopharyngeal carcinoma stem cell depletion score for each patient by using single sample gene enrichment analysis ssGSEA; collecting blood marker data of the same batch of patients, including 21 blood routine data, and performing data preprocessing; creating a stem cell depletion scoring model based on the blood marker, and training 21 blood routine data of a nasopharyngeal carcinoma patient by using an artificial neural network ANN algorithm to obtain a trained model; joint visualization is carried out through SHAP feature importance, and the effectiveness of senescence scoring and blood scoring is evaluated by combining correlation analysis and survival analysis; and collecting blood marker data of another batch of patients, performing data preprocessing, inputting the data into the trained model to obtain a score corresponding to each patient, and performing survival analysis to verify the efficiency of the model. According to the invention, effective and low-cost individual aging prediction can be realized.

The application discloses a kind of microcolumn-photon crystal composite device and preparation method thereof for multiple blood markers detection, wherein the composite device includes flexible substrate to distribute each microcolumn on the flexible substrate;Flexible substrate is curled to form a three-dimensional capillary channel, and each microcolumn is distributed on the inner wall of three-dimensional capillary channel;The surface of each microcolumn is covered with photon crystal for enhancing the sensitivity of low-concentration biomarker detection.The composite device and preparation method thereof form a three-dimensional capillary channel by curling flexible substrate, promote rapid and stable liquid transmission, effectively overcome the limitations of traditional plane substrate;By covering the surface of each microcolumn with photon crystal, the sensitivity of low-concentration biomarker detection can be enhanced when detecting.

The invention discloses an intelligent ICU monitoring management system, and relates to the technical field of ICU supervision. The intelligent I CU monitoring management system comprises a deployment and data acquisition module; a compensatory marker in blood is obtained, and intracranial pressure micro-vibration generated by cerebral blood flow pulsation is captured; a bionic compensation module; obtaining the compensation characteristic value of each organ; an environment linkage module; the logic configuration module is used for realizing real-time dynamic coupling of an I CU physical environment and a physiological state of a patient and establishing trigger logic of environment linkage; a nerve regulation module; and performing nerve regulation and control on the patient by combining the trigger logic of the blood compensation marker signal and the vibration signal. Blood markers and intracranial pressure micro-vibration signals are synchronously collected through the microenvironment probe and the piezoelectric film array, a multi-organ compensation model is constructed in combination with the bionic compensation module, the limitation of traditional single-parameter monitoring is broken through, compensation characteristics of a single organ can be recognized, the whole-body compensation state can be reflected through multi-organ coupling analysis, and the compensation accuracy of the whole body is improved. And the potential risk can be recognized earlier.

The invention relates to a chemiluminiscence detection kit for a blood marker pTau217 of an Alzheimer's disease and application of the chemiluminiscence detection kit. The kit comprises a magnetic microsphere suspension coated with a pTau217 capture antibody; a pTau217 detection antibody labeled by PEG12 (Polyethylene Glycol) < 12 > biotin; streptavidin marked by acridinium ester; an interference eliminating liquid; a washing liquid; pre-excitation liquid and excitation liquid. A PEG12-biotin-streptavidin system is introduced, a large amount of acridinium ester is coupled through streptavidin, a total luminescence signal is amplified, and the detection sensitivity and precision of the chemiluminescence pTau217 are greatly improved. Meanwhile, interference elimination liquid containing dioxane and Proclin300 is adopted and mixed with a plasma sample, then antibody capturing microspheres are added, non-specific adsorption of lipid and binding protein thereof in plasma on the surfaces of the microspheres is weakened, and the detection accuracy is greatly improved.

The invention discloses application of an interleukin 15 receptor subunit alpha (IL-15RA) blood biomarker as a marker for diagnosing idiopathic inflammatory myopathy (IIM), application of the IL-15RA blood biomarker in a reagent, application of the IL-15RA blood biomarker in a kit and application of the IL-15RA blood biomarker as an intervention target in preparation of a medicine for treating the idiopathic inflammatory myopathy (IIM). Serum proteomics screening of idiopathic inflammatory myopathy (IIM) is carried out by adopting an Olink proteomics technology, and a result shows that the serum level of IL-15RA in an IIM group is obviously higher than that of a healthy control group (average value, 2.04 vs.1.54 ng / mL, Plt; 0.01), the result difference has significance, and the result shows that the IL-15RA can be used as a novel blood marker of the IIM.

The invention provides a construction method and system of a colorectal cancer detection model, a blood marker for auxiliary diagnosis of colorectal cancer and a colorectal cancer detection device. The method comprises the following steps: acquiring target plasma samples of a plurality of research objects, and heating the target plasma samples; collecting headspace gas of the heated target plasma sample; vOCs in the headspace are detected and analyzed, and variables to be selected are obtained; screening the to-be-selected variables to obtain a target variable; acquiring a data set according to the target variable; constructing a colorectal cancer detection model; using the data set to train a colorectal cancer detection model; according to the construction method of the colorectal cancer detection model, modeling is carried out by detecting the difference of metabolic VOCs of the colorectal cancer and a control group of the colorectal cancer so as to distinguish and rapidly and nondestructively assist in diagnosis of the colorectal cancer, and help is provided for early diagnosis of the colorectal cancer.

This invention discloses an antibody for detecting apolipoprotein E4 and its application, specifically involving a detection antibody and kit for detecting ApoE4, a blood marker of Alzheimer's disease. Based on this antibody and kit, the presence of apolipoprotein E4 can be accurately detected.

The invention relates to an Alzheimer's disease blood marker flow type fluorescence luminescence multi-joint detection kit and application thereof. The Alzheimer's disease blood marker flow type fluorescence luminescence multi-joint detection kit comprises a capture microsphere mixed solution, a detection antibody mixed solution, a streptavidin-phycoerythrin conjugate, an interference elimination solution and a washing solution. The bihexanamide-biotin is labeled on the detection antibody, the steric hindrance of combination of the streptavidin-phycoerythrin conjugate and the biotin on the detection antibody is reduced through bihexanamide, more phycoerythrin can be combined on a single antibody, a fluorescence signal is remarkably enhanced, and the detection sensitivity is greatly improved. An interference elimination solution containing dimethyl sulfoxide and Proclin300 at the same time is adopted and mixed with a plasma sample, then a capture antibody and a detection antibody are added, non-specific adsorption of lipids and binding proteins thereof in plasma on the surfaces of microspheres is weakened, and the detection accuracy is greatly improved. According to the method, a machine learning model based on a logistic regression algorithm is constructed through a joint detection result of seven markers in three layers, and the judgment accuracy is cooperatively improved.

The invention provides application of a chronic inflammation comprehensive index or a 3C score in a prognosis prediction system of a II-III stage colorectal cancer patient, and belongs to the technical field of biomedicine. The method comprises the following steps: firstly, acquiring blood sample data of II-III stage colorectal cancer patients; then, according to the measured blood marker content, a chronic inflammation comprehensive index (CII) is calculated based on patient prognosis. And finally, predicting the recurrence-free lifetime and the total lifetime of the patient in combination with the CII value and the tumor position subgroup. In addition, the invention further provides an alternative scheme, namely, CII is replaced with 3C score, and the prognosis prediction accuracy of the colorectal cancer patient is further improved by measuring the content of carcino-embryonic antigen and carbohydrate chain antigen 19-9 in the body of the patient and CII and calculating the 3C score. The method disclosed by the invention has relatively high prediction accuracy and is expected to improve the prognosis of II-III stage colorectal cancer patients.

The application discloses a blood marker combination and kit for neurodegenerative diseases of lysosome function axis, and relates to the technical field of biomedical detection. The marker combination is composed of seven markers in three categories: glucocerebrosidase and cathepsin D; sphingolipids and gangliosides; and phosphorylated tau-217 protein, neurofilament light chain protein and glial fibrillary acidic protein. The application also provides an in-vitro diagnostic kit containing specific reagents for detecting the above markers, and constructs a risk assessment model based on a logistic regression or random forest algorithm. The marker combination and kit can be used for early screening, differential diagnosis, disease progression prediction and drug efficacy monitoring of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and neurogenic Gaucher disease, and have the advantages of high sensitivity, high specificity and minimally invasive detection.

The invention provides a Chinese ladiestresses root extract as well as a preparation method, a related product and application thereof, and belongs to the technical field of traditional Chinese medicine extraction. The preparation method comprises the following steps: mixing pedicularis chinensis and ketone, and performing reflux leaching and separation to obtain a leaching solution and medicine residues; recovering the solvent from the leaching solution to obtain a Chinese ladiestresses root extract; mixing the medicine residue with water, decocting, centrifuging the decoction, reserving the supernatant, and carrying out alcohol precipitation to obtain crude polysaccharide; reacting the crude polysaccharide with sodium periodate to obtain oxidized paniculate helminthostachys rhizome polysaccharide; and mixing 5-15 parts by weight of the paniculate helichrysum herb extract, 10-30 parts by weight of the oxidized paniculate helichrysum herb polysaccharide and 100 parts by weight of water, and carrying out ultrasonic dispersion and drying to obtain the paniculate helichrysum herb extract. The spiranthes sinensis extract obtained by the method can form a submicron-level particle structure, and can better reduce the foot swelling score of rheumatoid arthritis mice, improve the blood marker index of model mice and reduce the occurrence of hemolysis side effects.

The invention discloses an antibody for detecting beta-amyloid protein and application thereof, and particularly relates to a detection antibody and a kit for detecting Alzheimer's disease blood markers A beta 1-40 and A beta 1-42, the kit comprises three antibodies aiming at different antigenic determinants of beta-amyloid protein, based on the antibody and the kit, the existence of beta-amyloid protein can be accurately detected.

The application discloses a kind of S wave band high-power microwave biological effect test and evaluation method, comprising: selecting microwave test site satisfying far-field condition and constructing S frequency band high-power microwave biological effect device;According to test scheme, adjust output power, repetition frequency, pulse width and irradiation time to form different irradiation conditions, and apply S wave band high-power microwave irradiation to the biological body to be measured;At the preset time point after irradiation ends, the behavior of the biological body to be measured is tested and blood routine and biochemical index detection is carried out;Based on the obtained behavior characteristic data, blood routine and biochemical index data, a multi-parameter collaborative evaluation model of the three-level mapping relationship between physical stimulation intensity, behavior abnormality and blood markers is established to evaluate the influence of S wave band high-power microwave on the biological body.The application can study the influence of S wave band high-power microwave on the behavior state and blood routine parameters of the biological body under the conditions of output power, repetition frequency, pulse width, irradiation time and other variables.

The application provides a gold-silver alloy nanoflower SERS substrate and a preparation method and application thereof. 3+ and Ag + The preparation method is as follows: an aluminum foil paper substrate is placed in a growth solution containing Au 3+ and Ag + , a gold-silver alloy nanoflower array pattern layer with a multi-level branch structure is formed on the surface of the aluminum foil paper substrate by a displacement reaction of aluminum and noble metal ions in situ. The gold-silver alloy nanoflower array pattern layer has rich nanotips and a three-dimensional rough structure, can form a large number of electromagnetic 'hot spots', and can significantly enhance the Raman signal intensity. Relying on the excellent SERS enhancement performance, the gold-silver alloy nanoflower SERS substrate is applied to an immune recognition mediated sandwich detection mode, and high-sensitivity and accurate detection of a hidden blood marker in a fecal sample is realized. The preparation process is simple, the cost is low, and complex equipment is not needed; the obtained SERS substrate has strong stability and excellent repeatability, and can meet the needs of early screening and on-site rapid detection of digestive diseases.

Using deep metagenomic sequencing of individual gut microbiomes, coupled with techniques such as detailed long-term diet, fasting, and same-meal postprandial cardiometabolic blood markers analyses, intestinal microbes (defined by clusters of genomes referred to as species-level genome bins (SGBs)) have been identified as associated with different conditions and / or habits. Techniques are disclosed for using food guidance to intentionally alter the composition of the microbiome of an individual. Such alteration may include increasing the presence, abundance, or relative abundance of pro-health indicator microbe(s) and / or decreasing the presence, abundance, or relative abundance of poor health indicator microbe(s).

The invention relates to the technical field of biomedical detection, and discloses a plasma biomarker protein determination method for breast cancer detection, the non-invasive detection of breast cancer is realized by detecting the WFIKKN2 protein level in plasma through ELISA, and the method comprises the steps of collection and treatment of a plasma sample, ELISA detection and diagnosis result determination based on a specific threshold. The problems that in an existing breast cancer monitoring method, biopsy applicability is poor, CT / MRI has radiation and cost are solved, the defect that an existing blood marker is insufficient in sensitivity is overcome, and the method has the advantages of being high in sensitivity, easy and convenient to operate, low in cost, high in safety and the like and can be effectively used for breast cancer detection, illness condition grading and postoperative monitoring.

The present invention relates to a structure for surface-enhanced Raman scattering spectroscopy, a method for manufacturing the same, and a diagnostic method using the same. According to the structure for surface-enhanced Raman scattering spectroscopy, the method for manufacturing the same, and the diagnostic method using the same of the present invention, it is possible to provide a structure for surface-enhanced Raman scattering spectroscopy, which can be used as a surface-enhanced Raman scattering spectroscopy, even if there is no biomarker having excellent diagnostic performance in blood indexes. A structure for surface-enhanced Raman scattering spectroscopy, which can be used even for intractable cancers such as pancreatic cancer and intractable diseases, and a method for producing the same. Further, a diagnostic method and a diagnostic system using a surface-enhanced Raman scattering spectrum can be provided by the structure for the surface-enhanced Raman scattering spectrum.

The invention discloses a muscle quality assessment aided decision-making method based on double-source features, which comprises the following steps: firstly, collecting multi-modal data of a patient, extracting modal features, then adopting time sequence enhancement, obtaining DXA whole body, DXA leg and blood test features, and then carrying out modal correlation calculation, namely, calculating the correlation among the modal features of the DXA whole body, the DXA leg and blood test three modes; then, a relation graph between modes is constructed through graph convolution, mode relation fusion is carried out, finally, muscle quality prediction is carried out, and muscle quality evaluation is completed. According to the method, the DXA whole body and leg images and the double-source features of blood indexes are utilized, multi-modal relation modeling and time sequence enhancement are combined, high-precision explainable prediction of muscle quality is achieved, the whole body and leg muscle features can be distinguished, blood test changes can be dynamically reflected, and auxiliary decision support is provided for sarcopenia screening.

The application belongs to the field of molecular diagnosis, and discloses application of a blood marker in preparation of a diagnostic reagent for idiopathic benign paroxysmal positional vertigo. It is found for the first time that LRG1 in blood is obviously increased in the acute attack period of idiopathic benign paroxysmal positional vertigo, which indicates that the increase of blood LRG1 is a blood marker for dizziness of idiopathic benign paroxysmal positional vertigo, and can be used as auxiliary diagnosis in clinic.